joint venture
Replay, MD Anderson Venture Syena Bets on NK Cells to Bring TCR Therapy to Solid, Blood Cancers
Premium
After launching the first therapy, NY-ESO-1 TCR/IL-15 NK, in a multiple myeloma trial earlier this month, Syena is exploring the approach in new targets and tumor types.
Syena Starts Cell Therapy Trial in NY-ESO-1-Positive Multiple Myeloma
The Replay and MD Anderson subsidiary has treated the first multiple myeloma patient with its cord blood-derived TCR-NK cell therapy in a Phase I/II trial.
Arima Genomics, Protean BioDiagnostics Launch 3D Genomics Cancer Testing Joint Venture
The new firm, Aventa Genomics, will offer through its Orlando lab a clinical next-generation sequencing test for gene fusions, translocations, and rearrangements.
BostonGene, NEC, JIP Partner to Form Japanese Precision Oncology Joint Venture
The joint venture, called BostonGene Japan, aims to advance personalized cancer therapies and develop novel precision medicine approaches.
AstraZeneca Licenses Claudin 18.2-Targeted Antibody-Drug Conjugate From KYM Biosciences
The firm will pay $63 million upfront for global rights to CMG901, which is currently in development for Claudin 18.2-positive tumors including gastric cancers.